Sei Investments Co. Has $2.19 Million Stock Position in Ocular Therapeutix, Inc. $OCUL

Sei Investments Co. boosted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 52.2% in the first quarter, Holdings Channel.com reports. The firm owned 258,164 shares of the biopharmaceutical company’s stock after purchasing an additional 88,491 shares during the period. Sei Investments Co.’s holdings in Ocular Therapeutix were worth $2,187,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC raised its stake in shares of Ocular Therapeutix by 124.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,242 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new stake in shares of Ocular Therapeutix during the 4th quarter valued at about $31,000. Hilton Head Capital Partners LLC bought a new stake in shares of Ocular Therapeutix in the 4th quarter valued at approximately $42,000. Atlas Capital Advisors Inc. bought a new stake in shares of Ocular Therapeutix in the 4th quarter valued at approximately $61,000. Finally, State of Wyoming acquired a new position in Ocular Therapeutix in the fourth quarter worth approximately $78,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on OCUL. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price (up from $21.00) on shares of Ocular Therapeutix in a research note on Thursday, June 18th. Robert W. Baird increased their price target on shares of Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Needham & Company LLC reissued a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, May 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Ocular Therapeutix presently has a consensus rating of “Moderate Buy” and an average price target of $25.75.

Insider Transactions at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,156 shares of Ocular Therapeutix stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total value of $173,479.20. Following the transaction, the insider owned 2,597,170 shares in the company, valued at $21,296,794. This trade represents a 0.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 28,999 shares of company stock valued at $237,792. Company insiders own 3.10% of the company’s stock.

Ocular Therapeutix Stock Up 5.1%

Shares of Ocular Therapeutix stock opened at $9.19 on Friday. Ocular Therapeutix, Inc. has a 12-month low of $6.23 and a 12-month high of $16.44. The company has a quick ratio of 14.73, a current ratio of 13.10 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average price of $9.15 and a two-hundred day moving average price of $9.11. The stock has a market capitalization of $2.02 billion, a P/E ratio of -6.47 and a beta of 0.93.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The company had revenue of $13.47 million for the quarter, compared to analyst estimates of $13.20 million. During the same quarter last year, the firm posted ($0.39) earnings per share. The company’s quarterly revenue was down .1% compared to the same quarter last year. Equities analysts expect that Ocular Therapeutix, Inc. will post -1.5 earnings per share for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.